EUCTR2022-003743-10-DE招募中1 期
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 203
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Willing and able to give informed consent, with written informed consent available before any study assessments.
- •2. Male and female participants, age 18 to 75 years at the time of informed consent.
- •3. At least moderate major depressive disorder (MDD), (single or recurrent episode as informed by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5] criteria; if single episode, duration of =3 months and = 2 years) based on medical records, clinical assessment, and documented completion of the version 7.0.2 Mini International Neuropsychiatric Interview (MINI). For clarification, if recurrent MDD, there is no limit on episode duration.
- •4. Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments, in the current episode, based on the MGH ATRQ assessment. Augmentation with an add-on treatment counts as a second treatment. Participants must not have failed more than 5 prior pharmacological treatments current episode (psychotherapy is not counted towards treatment failure). For clarification, pharmacological treatments initially effective but subsequently ineffective (tachyphylaxis) will be considered treatment failures if they fulfil the ATRQ criteria for dose and duration of failure.
- •5. Hamilton Depression Rating Scale (HDRS) (17 item) score =19 at Screening (Visit 1) and baseline (Day -3).
- •6. CGI-S =4 at Screening and baseline (Day -3).
- •7. If currently taking antidepressant medications, willing and able to
- •discontinue current antidepressants including selective serotonin reuptake inhibitor, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and any augmentation medication such as antipsychotics or lithium. Withdrawal will follow local treatment guidelines and should aim to avoid withdrawal symptoms by gradually reducing the antidepressant
- •treatment dose.
- •8. Able (in the investigator’s opinion) and willing to undertake and comply with all study requirements, including ability to complete all protocol required assessment tools and to comply with all study visits in language used by study site.
- •9. Willing to abstain from alcohol for 48 hours before Day 1.
- •10. Willing to abstain from recreational drugs from Screening until the end of the study.
- •Intermittent use of cannabinoids prior to Screening is not exclusionary as long as the participant does not meet the criteria for substance use disorder, as assessed using the DSM-5.
- •11. Willing to allow their own general practitioner, and consultant if appropriate, to be informed of study participation.
- •1. Participants who complete the CORE study.
- •2. Willing and able to give informed consent for the OLE.
- •3. Willing to abstain from alcohol for 48 hours before OLE Day 1.
- •4. Willing to abstain from recreational drugs throughout the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 23
排除标准
- •1. Use of cannabinoids is not allowed for the duration of the study. Participants should not be administered the study drug if they have a positive urine drug screen result for cannabinoids pre-dose on Day 1 (retesting is allowed if there is a suspected false positive test).
- •2. Current or past history of schizophrenia, post-traumatic stress disorder, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder as assessed by medical history and a structured clinical interview (MINI).
- •3. Current personality disorders: Cluster A (paranoid, schizoid, schizotypal), Cluster B (antisocial, borderline, histrionic, narcissistic), or Cluster C (avoidant, dependent, -obsessive compulsive) assessed via McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD), MINI, and clinical judgement.
- •4. First-degree family history of schizophrenia, bipolar disorder, delusional disorder, or schizoaffective disorder.
- •5. Current (within the last year) alcohol or substance use disorder (other than caffeine or nicotine) according to DSM-5 and assessed by the MINI at Screening that in the opinion of the investigator will be a safety concern for enrollment in the study or that could interfere with the therapeutic process or with other aspects of study participation. Any participant who is not able to agree or adhere to a plan to reduce and manage use will be excluded.
- •6. A participant who at any time has been unresponsive to ketamine or esketamine, unresponsive to an adequate course of treatment with electroconvulsive therapy (ECT) defined as at least 7 treatments with unilateral/bilateral ECT, or has received vagal nerve stimulation or has received deep brain stimulation.
- •7. Currently receiving prohibited medications or therapy.
- •8. Suicidal ideation with some intent to act within 12 months prior to the start of Screening, per the investigator’s clinical judgement or based on the C-SSRS, corresponding to a response of Yes” on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) for suicidal ideation on the C-SSRS, or any suicidal behavior within the 12 months prior to the start of Screening. Participants reporting suicidal ideation with intent to act or suicidal behavior as assessed on Day 1 should be excluded.
- •9. Suicide attempt and/or self-injurious behavior within the last 12 months prior to Screening.
- •10. Depression is secondary to other severe medical conditions according to the investigator’s opinion.
- •11. Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to the study medication.
- •12. Any other clinically significant psychiatric condition that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study.
- •Further medical exclusion criteria are listed in the protocol.
- •1. Currently taking antidepressant medication.
- •2. Currently taking any other prohibited medication.
- •3. Participants who, in the opinion of the investigator, are not suitable to participate in the OLE.
- •4. Participants who met the Subject Dosing Stopping Criteria in the CORE.
- •5. Participants with controlled hypertension on antihypertensive therapy are excluded if repeated clinic seated or semi-recumbent sys
研究者
相似试验
招募中
1 期
Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant DepressioTreatment-Resistant Depression (TRD)MedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2022-003743-10-PLBeckley Psytech Ltd.225
已完成
2 期
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity DiseaseObesityJPRN-jRCT2080223753ovartis Pharma K.K.130
已完成
1 期
Single and Multiple Dose Study of MK-1942 in Healthy Japanese AdultsJPRN-jRCT2031210214Tanaka Yoshiyuki48
招募中
1 期
Single and Multiple Dose Study of MK-1167 in Healthy Japanese ParticipantsDementia Alzheimer's typeJPRN-jRCT2031230399Tanaka Yoshiyuki64
进行中（未招募）
1 期
A Randomised, Single Dose Exposure Study to Assess the Safety, Tolerability and Pharmacokinetics of Investigational Captisol-Enabled® Budesonide InhalationSolution (CBIS) Delivered via eFlow® Nebuliser and Conventional BudesonideInhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® JetNebuliser in Children with AsthmaAsthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-004035-30-GBVerus Pharmaceuticals Inc18